TCS 1102

CAS No. 916141-36-1

TCS 1102 ( TCS 1102, TCS1102, TCS-1102 )

Catalog No. M17659 CAS No. 916141-36-1

TCS 1102 is an effective, dual orexin receptor antagonist (Ki: 0.2/3 nM for OX2/1 receptors).

Purity : 97%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 51 In Stock
10MG 81 In Stock
25MG 158 In Stock
50MG 291 In Stock
100MG 408 In Stock
500MG 945 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TCS 1102
  • Note
    Research use only, not for human use.
  • Brief Description
    TCS 1102 is an effective, dual orexin receptor antagonist (Ki: 0.2/3 nM for OX2/1 receptors).
  • Description
    TCS 1102 is a potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively). TCS 1102 inhibits ADL-orexin B-mediated locomotion following i.p. administration in vivo and blocks orexin-A (Cat.No.1455) mediated increases in feeding behaviour.
  • Synonyms
    TCS 1102, TCS1102, TCS-1102
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    OX1; OX2
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    916141-36-1
  • Formula Weight
    470.59
  • Molecular Formula
    C27H26N4O2S
  • Purity
    97%
  • Solubility
    DMSO : ≥ 100 mg/mL; 212.50 mM
  • SMILES
    Cn1c2ccccc2nc1SCC(=O)N1CCC[C@H]1C(=O)Nc1ccccc1c1ccccc1
  • Chemical Name
    (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bergman JM, et al. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1425-30.
molnova catalog
related products
  • THZ 531

    THZ 531 (THZ531) is a first-in-class, selective CDK12 and CDK13 covalent inhibitor with IC50 of 158 nM and 69 nM, respectively.

  • MC180295

    MC180295 (MC-180295, MC 180295) is a novel potent, highly selective CDK9 inhibitor with IC50 of 5 nM

  • THZ-1

    A potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM; displays broad-based activity a subset of cancer cell lines with IC50s of <200 nM.